Mymetics Corporation – OTC:MYMX
Mymetics stock price today
Mymetics key metrics
Market Cap | 7.89M |
Enterprise value | 77.07M |
P/E | -0.67 |
EV/Sales | 25693.05 |
EV/EBITDA | -32.46 |
Price/Sales | 1721.29 |
Price/Book | -0.08 |
PEG ratio | N/A |
EPS | -0.03 |
Revenue | 359.65K |
EBITDA | -2.45M |
Income | -11.06M |
Revenue Q/Q | -71.54% |
Revenue Y/Y | -16.35% |
Profit margin | -170900% |
Oper. margin | -56766.67% |
Gross margin | -39600% |
EBIT margin | -56766.67% |
EBITDA margin | -682.88% |
create your own Smart Feed
Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.
Sign up for freeMymetics stock price history
Mymetics stock forecast
Mymetics financial statements
| Dec 2022 | 118.32K | -1.32M | -1121.48% |
|---|---|---|---|
| Mar 2023 | 3K | -942K | -31400% |
| Jun 2023 | 201.34K | -7.68M | -3816.87% |
| Sep 2023 | 36.98K | -1.11M | -3011.95% |
| Dec 2022 | 7321000 | 72.21M | 986.44% |
|---|---|---|---|
| Mar 2023 | 7324000 | 74.08M | 1011.48% |
| Jun 2023 | 533000 | 74.98M | 14068.29% |
| Sep 2023 | 100000 | 75.67M | 75670% |
| Dec 2022 | -321K | 34 | 236K |
|---|---|---|---|
| Mar 2023 | -478K | 0 | 500K |
| Jun 2023 | -604K | 92K | 588K |
| Sep 2023 | -335K | 2K | -2K |
Mymetics alternative data
| Aug 2023 | 11 |
|---|---|
| Sep 2023 | 2 |
| Oct 2023 | 2 |
| Nov 2023 | 2 |
| Dec 2023 | 2 |
| Jan 2024 | 2 |
| Feb 2024 | 2 |
| Mar 2024 | 2 |
| Apr 2024 | 2 |
| May 2024 | 2 |
| Jun 2024 | 2 |
| Jul 2024 | 2 |
Mymetics other data
| Period | Buy | Sel |
|---|---|---|
| Jul 2010 | 0 | 150000 |
| Transaction | Date | Insider | Security | Shares | Price per share | Total value | Source |
|---|---|---|---|---|---|---|---|
Option | KEMPERS RONALD HUGO GERARD officer: Presiden.. | Common Stock | 3,000,000 | $0.02 | $60,000 | ||
Sale | MARTIN JACQUES FRANCOIS officer: CEO | Common Stock | 150,000 | $0.2 | $30,000 | ||
Sale | ROCHET CHRISTIAN director | Common Stock | 1,917,276 | $0.17 | $333,606 | ||
Purchase | ROCHET CHRISTIAN director, officer: CEO, President | Common Stock | 6,000,000 | N/A | N/A |
| Insider | Compensation |
|---|---|
| Dr. Sylvain Fleury (1962) Chief Scientific Officer | $318,720 |
| Mr. Ronald Kempers (1968) Chief Executive Officer, Pres & Chief Financial Officer | $318,720 |
-
What's the price of Mymetics stock today?
One share of Mymetics stock can currently be purchased for approximately $0.03.
-
When is Mymetics's next earnings date?
Unfortunately, Mymetics's (MYMX) next earnings date is currently unknown.
-
Does Mymetics pay dividends?
No, Mymetics does not pay dividends.
-
How much money does Mymetics make?
Mymetics has a market capitalization of 7.89M.
-
What is Mymetics's stock symbol?
Mymetics Corporation is traded on the OTC under the ticker symbol "MYMX".
-
What is Mymetics's primary industry?
Company operates in the Healthcare sector and Biotechnology industry.
-
How do i buy shares of Mymetics?
Shares of Mymetics can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
-
Who are Mymetics's key executives?
Mymetics's management team includes the following people:
- Dr. Sylvain Fleury Chief Scientific Officer(age: 63, pay: $318,720)
- Mr. Ronald Kempers Chief Executive Officer, Pres & Chief Financial Officer(age: 57, pay: $318,720)
-
How many employees does Mymetics have?
As Jul 2024, Mymetics employs 2 workers.
-
When Mymetics went public?
Mymetics Corporation is publicly traded company for more then 25 years since IPO on 3 Apr 2000.
-
What is Mymetics's official website?
The official website for Mymetics is mymetics.com.
-
How can i contact Mymetics?
Mymetics can be reached via phone at +41 21 653 45 35.
Mymetics company profile:
Mymetics Corporation
mymetics.comOTC
9
Biotechnology
Healthcare
Mymetics Corporation, a vaccine company, engages in the research and development of vaccines for infectious and life disabling diseases in Switzerland. The company's product pipeline includes various vaccine candidates, such as HIV-1/AIDS, Covid-19, intra nasal influenza, respiratory syncytial virus, malaria, and chikungunya. Mymetics Corporation has a collaboration agreement with Texas Biomedical Research Institute; PATH Malaria Vaccine Initiative and the Laboratory of Malaria Immunology and Vaccinology of the National Institute of Allergy and Infectious Diseases to develop and produce virosome based vaccine formulations for a malaria transmission-blocking vaccine candidate; and Sanofi Pasteur Biologics, LLC to investigate the immunogenicity of influenza vaccines. The company was formerly known as ICHOR Corporation and changed its name to Mymetics Corporation in July 2001. Mymetics Corporation was founded in 1990 and is based in Epalinges, Switzerland.
Epalinges, 1066
CIK: 0000927761
ISIN: US62856A1025
CUSIP: 62856A102
